TY - JOUR
T1 - Role of 18FDG PET/CT in patients treated with 177Lu-DOTATATE for advanced differentiated neuroendocrine tumours
AU - Severi, Stefano
AU - Nanni, Oriana
AU - Bodei, Lisa
AU - Sansovini, Maddalena
AU - Ianniello, Annarita
AU - Nicoletti, Stefania
AU - Scarpi, Emanuela
AU - Matteucci, Federica
AU - Gilardi, Laura
AU - Paganelli, Giovanni
PY - 2013
Y1 - 2013
N2 - Purpose The prognostic value of FDG PET for neuroendocrine tumours (NETs) has been reported. In this study we evaluated the role of FDG PET in predicting response and progression-free survival (PFS) after 177Lu-DOTATATE peptide receptor radionuclide therapy (Lu-PRRT) in patients with advanced well-differentiated grade 1/2 NETs. Methods We retrospectively evaluated 52 patients with progressive advanced NETs overexpressing somatostatin receptors and treated with Lu-PRRT with a cumulative activity up to 27.7 GBq divided into five courses. According to WHO 2010/ENETS classification, patients were stratified into two groups: those with grade 1 tumour (Ki-67 index ≤2 %, 19 patients), and those with grade 2 tumour (Ki-67 index >3 % to 2.5) were frequently associated with more aggressive disease. PET+ patients with grade 2 NET, 32 % of whom did not respond to Lu-PRRT monotherapy, might benefit from more intensive therapy protocols, such as the combination of chemotherapy and PRRT.
AB - Purpose The prognostic value of FDG PET for neuroendocrine tumours (NETs) has been reported. In this study we evaluated the role of FDG PET in predicting response and progression-free survival (PFS) after 177Lu-DOTATATE peptide receptor radionuclide therapy (Lu-PRRT) in patients with advanced well-differentiated grade 1/2 NETs. Methods We retrospectively evaluated 52 patients with progressive advanced NETs overexpressing somatostatin receptors and treated with Lu-PRRT with a cumulative activity up to 27.7 GBq divided into five courses. According to WHO 2010/ENETS classification, patients were stratified into two groups: those with grade 1 tumour (Ki-67 index ≤2 %, 19 patients), and those with grade 2 tumour (Ki-67 index >3 % to 2.5) were frequently associated with more aggressive disease. PET+ patients with grade 2 NET, 32 % of whom did not respond to Lu-PRRT monotherapy, might benefit from more intensive therapy protocols, such as the combination of chemotherapy and PRRT.
KW - 177Lu-DOTATATE
KW - FDG PET
KW - Neuroendocrine tumours
KW - PRRT
UR - http://www.scopus.com/inward/record.url?scp=84888343316&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84888343316&partnerID=8YFLogxK
U2 - 10.1007/s00259-013-2369-z
DO - 10.1007/s00259-013-2369-z
M3 - Article
C2 - 23443937
AN - SCOPUS:84888343316
VL - 40
SP - 881
EP - 888
JO - European Journal of Pediatrics
JF - European Journal of Pediatrics
SN - 0340-6199
IS - 6
ER -